Methods for producing compositions containing plasmalogen
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11517594-B2
Publication Date
2022-12-06
Expiration Date
Abstract
Provided is a method for producing a composition containing plasmalogen derived from a plasmalogen-containing animal tissue, the method being without significantly decreasing an amount of plasmalogen derived the plasmalogen-containing animal tissue. A method for producing a composition containing plasmalogen derived from an animal tissue, the method comprising: (A) concentrating an alcohol extract of a plasmalogen-containing animal tissue, and (B) after diluting a concentrated product obtained by (A), allowing to stand under refrigeration.
Core Innovation
The invention provides a method for producing a composition containing plasmalogen derived from plasmalogen-containing animal tissue. The method includes concentrating an alcohol extract of the plasmalogen-containing animal tissue, diluting a concentrated product obtained by concentrating the alcohol extract, and keeping the diluted product under refrigeration.
The problem addressed is preventing significant loss of plasmalogen during processing and handling, particularly when the diluted product is kept under refrigeration rather than kept at normal temperature. The diluted product is maintained under refrigeration at 2 to 150C, and in additional embodiments the refrigeration is maintained for 1 to 7 days.
The invention further relates to plasmalogen-containing animal tissue as dried material, including drying by blowing air in a temperature range of 25 to 590C. Characterization and/or defining of the plasmalogen-containing composition is described using groups corresponding to the aliphatic hydrocarbon portion of docosahexaenoic acid and/or eicosapentaenoic acid.
Claims Coverage
The partial content includes one independent claim with a method structure of concentrating an alcohol extract, diluting the concentrated product, and keeping the diluted product under refrigeration at 2 to 150C. The cited dependent claims add further constraints on refrigeration duration, tissue form, drying, taxonomic source, and plasmalogen characterization via specific groups.
Concentrating alcohol extract of plasmalogen-containing animal tissue and diluting the concentrated product
A method that includes concentrating an alcohol extract of a plasmalogen-containing animal tissue, obtaining a concentrated product, and diluting the concentrated product to obtain a diluted product.
Keeping the diluted product under refrigeration at 2 to 150C
Keeping the diluted product obtained after diluting the concentrated product under refrigeration, wherein the refrigeration is carried out at 2 to 150C.
Maintaining refrigeration for 1 to 7 days
In a further limitation, keeping the diluted product under refrigeration is maintained for 1 to 7 days.
Using dried plasmalogen-containing animal tissue
In a further limitation, the plasmalogen-containing animal tissue is provided as a dried material.
Drying animal tissue by blowing air at 25 to 590C
In a further limitation, drying the animal tissue is carried out by blowing air at 25 to 590C.
Limiting source to aquatic invertebrates in a defined taxonomic scope
In a further limitation, the aquatic invertebrates are within Phylum Chordata, Subphylum Urochordata, and Class Ascidiacea, and are further limited to the genus Halocynthia.
Plasmalogen defined by a group corresponding to the aliphatic hydrocarbon portion of DHA/EPA
In a further limitation, the plasmalogen derived from animal tissue contains a group corresponding to the aliphatic hydrocarbon portion of docosahexaenoic acid or eicosapentaenoic acid.
Across the independent claim and cited dependent claim limitations, the core inventive coverage focuses on producing a plasmalogen-containing composition by concentrating an alcohol extract of plasmalogen-containing animal tissue, diluting the concentrated product, and keeping the diluted product under refrigeration at 2 to 150C. The additional described limitations further specify refrigeration duration, tissue form as dried material, drying conditions by blowing air, a defined aquatic invertebrate taxonomic source, and plasmalogen characterization using groups corresponding to DHA/EPA aliphatic hydrocarbon portions.
Stated Advantages
Prevents significant loss of plasmalogen when producing the plasmalogen-containing composition by keeping the diluted product refrigerated under the claimed temperature conditions.
Documented Applications
Food composition and pharmaceutical composition applications are described, including uses related to neurodegenerative and central nervous system inflammatory diseases such as Alzheimers disease and Parkinsons disease.
Interested in licensing this patent?